GLP-3 (RT) 10MG

Description

GLP-3 (RT) 10mg — retatrutide research peptide, Canada

Researched & reviewed by the SPO Quality Team · Last reviewed: 30 September 2026

GLP-3 (RT) is this shop’s name for retatrutide, a 39-amino-acid synthetic peptide that Eli Lilly built to act on the GIP, GLP-1 and glucagon receptors from a single molecule^[1]. No hormone called “GLP-3” exists; the batch report below is titled “Retatrutide” because that is what the laboratory tested for. Retatrutide is an investigational drug with published Phase 3 trials^[4] and no regulatory approval anywhere as of this review. This listing is one sealed vial of lyophilized research-grade peptide at a 10mg labelled amount, for laboratory use only; it is not the trial drug.

Full research overview, study table & references → GLP-3 (retatrutide) in Canada: research guide

Identity at a glance

This batch: certificate of analysis

Product tested	Retatrutide 10 mg (this listing, sold as GLP-3 (RT) 10mg)
Testing laboratory	Janoshik Analytical (independent)
Report number	#232263
Sample received / analysed	16 September 2026 / 21 September 2026
Measured content	9.24 mg per vial (labelled 10 mg)
Purity	99.079%
Verification key	LBUI98X8TRUG (checkable at janoshik.com)
Report	View the report image · COA library

What the document says: within Janoshik’s blind panel for GLP-1-class peptides (semaglutide, tirzepatide, retatrutide) the sample was identified as retatrutide, 9.24 mg of it was measured in a vial labelled 10 mg, and the purity by HPLC was 99.079%. Key LBUI98X8TRUG can be entered on janoshik.com to confirm the document. The same report is listed in the COA library for the 10mg pen. Check the lot on your label against it.

What researchers have looked at

• Receptor assays and obese mice (2022): balanced glucagon- and GLP-1-receptor activity with stronger GIP-receptor activity in vitro; in mice, lower body weight and better glycaemic control, with glucagon-receptor signalling adding energy expenditure^[1].
• Phase 1b, 72 adults with type 2 diabetes, 12 weeks: dose-proportional pharmacokinetics, a half-life of about six days, gastrointestinal disorders the most common adverse events, 29 early discontinuations^[2].
• Phase 2, 338 adults with obesity, 48 weeks: dose-dependent body-weight reductions versus placebo; gastrointestinal events that rose with dose; a heart-rate increase that peaked at 24 weeks^[3]. Phase 3 TRIUMPH-2 (1,152 adults, 80 weeks) recorded more diarrhoea, nausea, hypotension and dysesthesia than placebo and up to 12% permanent discontinuation^[4].
• Outside trials (2026): a case report of a man with type 1 diabetes who became acutely unwell after self-administering an online-bought “retatrutide” product^[5], and an analysis of the composition and label accuracy of such products in Australia^[6].

Those numbers belong to Eli Lilly’s investigational drug in registered trials. They are reported here as literature about the compound, not as properties of this vial, and no benefit is claimed for it.

Storage and handling

• Sealed vial at −20 °C for long-term storage (the site states up to 24 months as dry powder); cool, dry and dark for short periods; no repeated freeze–thaw.
• Reconstituted solutions are less stable than powder; prepare only what an experiment needs. No dosing, reconstitution or administration guidance is published on this site.

Other strengths: GLP-3 (RT) 5MG · GLP-3 (RT) 20MG · GLP-3 60MG · GLP-3 (Pen). Domestic shipping by Canada Post; the shipping policy has cut-off times, delivery estimates and the free-shipping threshold. The whole range is on the page where you can buy peptides online in Canada.

Frequently asked questions

Is GLP-3 (RT) 10mg the same thing as retatrutide?

Yes. GLP-3 (RT) is the catalogue name; the compound is retatrutide (LY3437943), an investigational triple GIP/GLP-1/glucagon receptor agonist (PMID 35985340). There is no hormone called GLP-3. The Janoshik report for this vial is titled “Retatrutide” and identified the sample within a blind panel of GLP-1-class peptides.

How is this GLP-3 (RT) 10mg batch verified?

By an independent laboratory. Janoshik report #232263 (sample received 16 September 2026, analysed 21 September 2026): identity confirmed as retatrutide, 9.24 mg measured against a 10 mg label, purity 99.079%, verification key LBUI98X8TRUG. The report is embedded above and filed in the COA library; match your lot to it before relying on it.

How should GLP-3 (RT) be stored?

Frozen at −20 °C in the sealed vial for long-term storage (the site states stability up to 24 months as lyophilized powder); cool, dry and dark for short periods; avoid freeze–thaw cycling. Solutions are less stable than the powder.

Is retatrutide approved, and is this vial for human use?

No and no. Retatrutide is an investigational drug with published Phase 2 and Phase 3 trials (PMIDs 37366315, 42810372) but no approval from Health Canada, the FDA or any other regulator as of 30 September 2026. This vial is research-grade material for laboratory use only, not for human or animal consumption, and Shop Peptides Online provides no dosing or administration guidance. A 2026 case report describes harm after self-use of an online-bought product sold as retatrutide (PMID 42669023).

References

1. Coskun T, Urva S et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. PMID 35985340
2. Urva S, Coskun T et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. PMID 36354040
3. Jastreboff AM, Kaplan LM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. PMID 37366315
4. Bellido V, le Roux CW et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. PMID 42810372
5. Branine N (2026). Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. PMID 42669023
6. Piatkowski T, Craven A et al. (2026). Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug Alcohol Rev. PMID 42559975

For laboratory research use only. Not for human or animal consumption. This description identifies the material and its documentation and summarises published literature on the investigational compound; it makes no claim of efficacy or safety for the material sold.